Aurobindo Pharma Share Price in Focus; Arm Acrotech Biopharma Launches ADQUEY Ointment in US

Aurobindo Pharma’s step-down subsidiary Acrotech Biopharma has launched ADQUEY (difamilast 1%) ointment in the US, according to a company press release dated September 30, 2026.  

The product is for mild-to-moderate atopic dermatitis in adults and children aged two years and above.  

Product Details 

ADQUEY is a non-steroidal topical phosphodiesterase 4 (PDE4) inhibitor. It contains 1% difamilast and is indicated for topical treatment of mild-to-moderate atopic dermatitis. Difamilast was originally discovered and developed by Otsuka Pharmaceutical Co., Ltd.  

Acrotech has a licence from Otsuka to commercialise the medicine in the United States. The company’s latest announcement covers both the product launch and the formation of a separate dermatology business within Acrotech.  

Dedicated Dermatology Division 

The new dermatology business will have functions covering marketing, sales, and field-based engagement. According to Acrotech, its work will include building awareness of ADQUEY, engaging with dermatology healthcare professionals and supporting patients during treatment.  

The division is also to develop the infrastructure and expertise required for Acrotech’s activities in specialty dermatology.  

US Dermatology Market 

ADQUEY is entering a market estimated at around US$1.3 billion for the 12 months ended July 2026, based on IQVIA MAT data. The figure refers to the market in which the product will compete.  

Aurobindo Pharma’s Business 

Acrotech Biopharma is a step-down subsidiary of Aurobindo Pharma and was formed to commercialise proprietary medicines. Aurobindo Pharma is headquartered in Hyderabad and develops, manufactures and commercialises generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients.  

The company has 31 manufacturing and packaging facilities and sells its products in more than 150 countries, according to the release. Its portfolio covers seven major therapeutic and product areas.  

Read More: SEAMEC Share Price in Focus; Enters $19.02 Million Charter Deal with G R Infraprojects for ONGC Projects! 

Aurobindo Pharma Share Price Performance  

As of October 1, 2026, 1:50 pm, Aurobindo Pharma share price was trading at ₹1,673.70, a 0.10% increase from the previous closing price. 

Conclusion 

The US launch puts Acrotech’s ADQUEY business alongside a newly formed dermatology division. The company will now operate dedicated marketing, sales, and field-based functions for the product and the wider dermatology business. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.